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Dear Editor,
In a recent publication in Lab Animal,1 a non-
human primate (NHP) researcher at the California
National Primate Research Center, USA, argued for
the continued importance of experiments on
macaques for better understanding HIV and AIDS,
and for tackling the virus and the disease with ther-
apies and vaccines. Though the stance of the author
is far from surprising, given his background and cur-
rent employer (an organisation which houses around
5000 monkeys for research), the paper, even as com-
prehensive as it is, is not sufficiently critical of NHP
experiments and overlooks a number of their defi-
ciencies and established problems with them. Given
the harm caused to the macaques in HIV/AIDS
research, it is essential that we adopt an ethical and
critical view, and that we seek ways of avoiding such
research at all costs, rather than non-critically seek-
ing to support and excuse it, often superficially.
What needs to be done
Attempts at conveying an ostensibly balanced view
are not enough. How “closely” do SIV-infected or
SHIV-infected macaques resemble HIV-infected
people? Do the differences between the model and
reality matter, and to what degree? Is it acceptable
to consider the NHP models as merely not being
“perfect”, when some would regard the evidence
against them to indicate that they are very poor
indeed, and of insufficient human relevance for
their use to be scientifically justifiable? Is it fair, at
the same time, to make the sweeping statement
that “there are currently no good [alternatives]”?
Shouldn’t the prevailing attitude be vice versa: that
the NHP models are ‘no good’, while the alterna-
tives are merely imperfect? Have NHP data really
provided essential data on HIV pathogenesis, which
could not have been obtained without NHP use, by
using a combination of in vitro, in silico, ex vivo and
clinical studies? How reliable is the extrapolation of
NHP data to humans, when the failures are fac-
tored in? It is not sufficient to claim that NHPs were
essential, simply because they were used in some
area of HIV research: to have been justifiable, the
data they provided must have been reliable, predic-
tive of human HIV infection and AIDS, not obtain-
able by other means, and crucial to a breakthrough
that resulted in human benefit. Even then, any-
thing from the past that meets these criteria has lit-
tle or no bearing on the current and future need for
NHP use, as alternatives continue to be developed
and improved and are increasingly comprehensive
and capable. The onus is on NHP researchers to
make a robust case addressing all the above, and
more — yet none has been offered to date.
Shortcomings of NHPs
There are, in fact, myriad criticisms and shortcom-
ings of using SIV-infected and SHIV-infected
NHPs that were not acknowledged — or at least
not sufficiently appreciated and discussed — in the
Lab Animal review, which is therefore, I believe,
more of an opinion piece than a critical analysis.
For example, my own review, at the time of writing
in 2008, showed that close to 100 varied preventive
and therapeutic HIV/AIDS vaccines had proceeded
into clinical trials based on encouraging safety and
efficacy data from animal tests, most (if not all)
involving NHPs including SIV/SHIV-infected
macaques and HIV-infected chimpanzees. In
greater than 200 clinical trials, none had shown
sufficient safety and efficacy — had ‘worked’ in
other words — to be approved for human use.2 This
represented more than two decades of disappoint-
ment in HIV vaccine clinical trials, since the first
in 1987. Almost another decade further on, these
numbers will be greater still, and we continue to
wait for a vaccine to work in people, while so many
have worked in NHPs. Some of these have been
high-profile failures after widespread and vocifer-
ous claims of promise and success: VaxGen’s
AIDSVAX vaccines, which failed to protect 7500
people in large trials;3 Merck’s V520 vaccine, “One
of the most promising [vaccines] to be tested on
people so far”4 whose ‘STEP study’ trials were ter-
minated after not only failing to protect thousands
of people from HIV infection, but actually increas-
ing their risk of infection;5,6 the failed PAVE 100
and Phambili trials,7 and the RV144 trial, which
failed to protect almost 16,500 trial participants.8
This can only be viewed as a staggering level of
failure, yet attempts are still being made by many
in the field to dress it all up as a learning experi-
ence — a series of well-intentioned dead ends that
will eventually lead to science going down a path
that will lead to success. Indeed, the author of the
Lab Animal article suggests that it merely indi-
cates the need to aim for “balance” in the immune
responses induced by vaccines, “circular feedback”
between NHP and human trials, and “optimisation
of the input variables of in vivo NHP vaccine stud-
ies, to enhance their predictability”. To be frank: to
advocate the continued manipulation of demon-
strably and unequivocally poor approaches to a
problem in the hope of solving it, is not scientific. To
use an old metaphor, the time has come for these
advocates to stop looking for their keys under the
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street lamp, just because they can see where
they’re looking, and to start looking elsewhere,
where they may actually find them. In other
words: to stop using monkeys, and move where the
science demands — to alternative methods, which
are human relevant, as well as humane.
In fact, misgivings about the NHP-oriented
direction of HIV/AIDS research in general have
been voiced for some time, within the field.e.g. 9–19
For example: “…efficacy of HIV-1 based vaccines
cannot be directly evaluated in the SIV model”;13
“Despite the similarity with infection of monkeys
by SIV, this has not proven a practical animal
model for studying vaccines”;9 “When it comes to
testing HIV vaccines, only humans will do”;10 “the
persistent view held by many that there is no pre-
dictive animal model for HIV infection in
humans”;15 “No animal models faithfully repro-
duce... HIV-1 infection and disease in humans, and
the studies of experimental vaccines in animal
models... have yielded disparate results”;17 “…the
crucial role of human testing in the development of
any vaccine… human immune system variability
or virus diversity can’t really be mimicked by any
of the currently used laboratory animal models”;18
“...current SHIV models do not reflect HIV-1 vari-
ants circulating globally and thus do not fully reca-
pitulate the viral factors that contribute to the
infection dynamics being studied”.19 In a 2008
essay in Nature, Dr Anthony Fauci, NIAID
Director and an AIDS expert, when reflecting on
the era of HIV/AIDS, noted that: “We must learn
from our missteps, build on our successes in treat-
ment and prevention, and renew our commitment
to developing the truly transforming tools that will
one day put this scourge behind us.”20 If such an
epic scale of vaccine failures is not a misstep, then
what is? As recently opined in a review in the lead-
ing journal, Science, we know that a preventive
vaccine for HIV is in principle possible: the prob-
lem is translating benefit seen in NHPs to benefit
for humans. As the authors stated, “What is not
known is how studies in monkeys will translate
into humans.”21 This honesty is refreshing, given
the passive acceptance of NHP data and their rel-
evance to humans so often seen in NHP HIV liter-
ature; but, given the available evidence of how
NHP data from SIV/SHIV/HIV research have
translated to humans over the years, this could be
more accurately conveyed as “It is very unlikely
that studies in monkeys will translate to humans.” 
General flaws with NHPs and lack of human
relevance
Part of the problem is that macaques are poorly
predictive of human drug responses generally, as
well as being poor models of HIV/AIDS — the Lab
Animal paper’s superficial claims of broad “similar
physiology and metabolism” do not withstand
scrutiny. It is acknowledged that macaque toxicol-
ogy data “can differ from humans as much as other
species”.22 In developmental toxicity tests, data
correlate with human data just 50% of the time,
less even than results from more evolutionarily-
distant species such as rats, hamsters and fer-
rets.23 There remains “no statistically credible
evidence” that NHP toxicology data “contribute
any predictive value, either separately or in combi-
nation” (for example, with dog data) to human tox-
icology;24 and for the prediction of drug-induced
liver injury, NHPs are less predictive than rodents,
which have failed to predict up to 51% of effects in
humans.25 Single-dose toxicity tests, to which 34%
of all non-human primates in regulatory safety
tests are subjected, have been scientifically dis-
credited.26 And my own, recent work shows that
macaque tests for drug toxicity are not fit for pur-
pose: if toxicity is absent in animal tests, indicat-
ing that a new drug may be ‘safe’ (or free from
adverse effects) in humans, the animal test pro-
vides almost no evidential weight to the probabil-
ity that this will be the case in people, too. In fact,
the data indicated that NHPs were even poorer
than other commonly-used animal species, such as
rodents and dogs.27
Why NHPs are poor models of human
HIV/AIDS
Importantly, we now know not only how NHP
HIV/AIDS research is poorly relevant to human
HIV/AIDS, but also why. Fundamental, wide -
spread, significant genetic differences are at the
root of the poor translation of data from NHPs to
humans in HIV/AIDS research, and mean that the
use of NHPs can never be judged to be scientifically
valid or necessary. Differences between both
humans and macaques, and between HIV and SIV,
have clear and serious consequences for NHP-based
research. In the course of my work, I have published
two papers on known genetic differences — in terms
of gene complement, expression and regulation —
between humans and chimpanzees,28 and between
humans and monkeys, notably mac aques.29 Both
papers list differences that impact the immune sys-
tem in general, and also the pathogenesis of
HIV/SIV in particular. Examples include: genomic
rearrangements, and differences in gene comple-
ment and regulation, including differences in
HLA/MHC alleles, which affect susceptibility to,
and the outcome of, HIV infection; differences in Fc
receptors that have implications for the develop-
ment and testing of vaccines and antibody thera-
pies; and differences in the TRIM5 gene — even
minor ones, resulting in single amino acid differ-
ences of the TRIM5 protein — which are responsible
for restricting and altering the host range of HIV
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and SIV viruses between different primates.
Indeed, macaques from different origins and geo-
graphical regions differ in their responses to SIV.
Rhesus macaques of Indian origin were used most
often, at one time, simply because this was the
species supplied to laboratories by breeding facili-
ties in the USA.30 Then, a shortage of these mon-
keys prompted a search for other sources, and
attention switched to the Chinese macaque, as it
was “more readily obtainable”. However, differences
in susceptibility to SIV infection and disease were
noted, mirroring differences also seen among
species of macaque (rhesus, cynomolgus and pig-
tailed). It was concluded that “...even subtle genetic
differences between two subspecies (races) of pri-
mate may promote significant differences in the
pathogenicity of the same virus”. With regard to the
viruses themselves: SIV and HIV-1 are only around
50% homologous by nucleic acid sequence, and crit-
ical genetic differences are acknowledged (and
should not be overlooked for convenience). For
example, SIV from sooty mangabeys and macaques
don’t contain the HIV vpu gene, but instead have
the vpx gene, which differs functionally.31–33
The end of chimpanzee use
These misgivings and caveats, and the biological
and genetic species differences underpinning them,
have translated into some significant changes in
practice. For example, in spite of continued, vocifer-
ous assertions from chimpanzee researchers that
chimpanzees had a “critical role in the testing of
potential [HIV] vaccines” and that they “are still
important for testing vaccines aimed at preventing
HIV-1 infection or reducing the virus load in
infected individuals”,34 funding for AIDS research
in chimpanzees reduced to vanishing point due to
its lack of human relevance (chimpanzees can be
infected with HIV, but don’t get AIDS). Indeed, so
sceptical was the US Food and Drug Admin -
istration (FDA) of chimpanzee data, that it permit-
ted clinical trials of two HIV/AIDS vaccines despite
data showing them to be ineffective in chim-
panzees.35 All of this was even prior to the US
Institute of Medicine’s ‘coup de grace’ inquiry into
chimpanzee research concluding in 2011 that these
(and other) claims had no substance.36 Chim -
panzee research, in HIV/AIDS and other areas, is
no more. I believe evidence shows it must be a mat-
ter of time for monkey research, too. This is not
only due to scientific evidence, and ethical consid-
erations: the public simply don’t want it. A UK poll
conducted on behalf of the government in 2014
found that just 37% of people agreed with the use
of animals in “all types of research”, with only 16%
accepting experiments on monkeys, even if they
clearly benefitted people.37 Across Europe, a 2009
poll revealed that 79% of people supported a new
law to “prohibit all experiments on animals which
do not relate to serious or life-threatening human
conditions”, with 84% agreeing this “should prohibit
all experiments causing severe pain or suffering to
any animal”;38 and in 2010, 56% of Euro peans
agreed that scientists should not experiment on
larger animals like dogs and monkeys, for the
improvement of human health and well-being.39
It must, of course, be acknowledged that deliver-
ing an HIV/AIDS vaccine is a monumentally diffi-
cult challenge. That is not in dispute. Yet, it must
also be acknowledged that billions of dollars and
many thousands of NHP lives have now delivered
around 100 vaccines of many types that work in
NHPs, but no vaccine that works in humans; and
that the insistence of NHP researchers that they
be allowed to press on with their ‘models’ regard-
less, is unscientific and borne of desperation rather
than logic and scientific reflection and evaluation.
In the light of a second article on NHPs in the
same issue of Lab Animal, citing the fact that a
staggering 62,000 NHPs (approx.) had been used
in research in the USA alone in 2015,40 the onus is
heavily on science to use better human-relevant
technologies that already exist and will deliver —
if given a fair chance. Studies of HIV-infected peo-
ple who are able to control and suppress the virus
(‘elite controllers’) in the absence of therapy, and
who do not develop AIDS, as well as of those who
respond to short-term treatment and who continue
to control the virus when treatment is halted
(‘post-treatment controllers’), are identifying the
immunologic factors involved and responsible, and
are pointing toward means of targeting and eradi-
cating reservoirs of HIV as part of a cure.41–43 In
vitro efforts continue to be immensely productive.
Recent examples include: elucidating the role of
HIV-infected Langerhans cells in inducing T-cell
immune responses;44 showing how follicular CD8
T-cells kill HIV-infected cells, suggesting they
could be a component of a cure;45 unravelling the
mechanism of NK-cell mediated control of HIV
infection;46 the discovery and development of HIV
entry (attachment and fusion) inhibitors47,48 and
integrase inhibitors49 as therapies; continued
‘omic’ analyses to identify host factors in HIV infec-
tion, and therefore new targets for interventions;50
the characterisation of HIV protein domains to
facilitate rational drug design;51 and, in combina-
tion with computer-based approaches, creating,
identifying and characterising a variety of
nanobodies (in effect, tiny antibodies) as new ther-
apies.52–56
Instead of embracing these superior techniques
and approaches, and appreciating the need to move
away from needlessly causing pain and suffering to
monkeys to generate poor data, the second Lab
Animal article reports on the NIH workshop on
NHPs held in September 2016, which, instead of
“conducting a larger review of its non-human pri-
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mate research” as requested by members of the US
Congress, focused on “Ensuring responsible over-
sight”. It quoted attendees, far from asking sorely-
needed questions of the human relevance of NHP
research, as seeking to “help the public understand
why we do research and why it helps human health”.
Until the attitude of NHP researchers changes to a
truly scientific one, reflecting on their chosen field
and asking critical questions of it, they will continue
to make excuses for it — and tens of thousands of
monkeys each year, as well as many millions of
humans relying on science to provide cures and
treatments for human diseases of many kinds, will
continue to suffer and to wait in vain.
Sincerely, 
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